The Indian pharmaceutical industry is undergoing a major transformation with new government initiatives aimed at boosting research and innovation. The Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, has recently announced the Promotion of Research and Innovation in Pharma MedTech (PRIP) scheme with a financial outlay of ₹5,000 crores. This scheme is set to make India a global leader in pharmaceutical research and development.
Overview of the PRIP Scheme 2025
The PRIP Scheme, launched under Gazette Notification No. 199 (17th August 2023), focuses on accelerating investments in the pharmaceutical and MedTech R&D ecosystem. Of the total ₹5,000 crores, ₹4,250 crores are allocated for enhancing R&D in critical areas.
Features of the PRIP Scheme
- Encourages Pharma & MedTech R&D – Focus on innovation in the pharmaceutical and medical technology sector.
- Funding for Priority Research Areas – Financial assistance is provided for cutting-edge research in six priority sectors.
- Support for Startups & MSMEs – Small businesses can receive funding to accelerate innovation.
- Collaborations with Research Institutions – Companies are encouraged to partner with government research bodies.
Priority Research Areas Covered Under PRIP
The government has identified six crucial R&D areas under this scheme:
- New Chemical & Biological Entities, Phyto-pharmaceuticals
- Complex Generics and Biosimilars
- Precision Medicine & Targeted Therapies
- Medical Devices & Healthcare Tech
- Orphan Drugs for Rare Diseases
- Drug Development for Antimicrobial Resistance (AMR)
Funding Categories for Pharma Companies
The PRIP scheme provides funding under three categories:
Category B I:
- Funding up to 35% of project cost or ₹125 Cr (whichever is less)
- Applicable to Pharma companies with ₹1,000 Cr+ annual revenue or MedTech firms with ₹250 Cr+ revenue
- Must spend 3-5% (Pharma) or 1-3% (MedTech) of revenue on R&D
Category B II:
- Funding up to ₹100 Cr or 35% of project cost
- Open for R&D projects at TRL 5 or 6
Category B III:
- Grants up to ₹1 Cr per project
- Specifically for Startups & MSMEs with early-stage projects (TRL 1 to TRL 4)
How to Apply for PRIP Scheme?
- Submit an Expression of Interest (EoI) before April 7, 2025
- Access the Digital EoI Form via the official PRIP Scheme webpage
- Ensure compliance with eligibility requirements and attach necessary documents
Why This Matters for Pharma Companies in Ankleshwar?
Ankleshwar, known as India’s largest industrial hub for pharmaceuticals, houses several WHO-GMP certified pharma firms. This new PRIP scheme presents an opportunity for pharma companies in Ankleshwar to:
- Expand R&D capabilities with government funding
- Develop advanced pharmaceutical products
- Enhance global competitiveness in drug innovation
Conclusion
With the PRIP Scheme 2025, the Government of India is taking a bold step toward strengthening the pharmaceutical R&D sector. Pharma companies, startups, and MedTech firms should take advantage of this opportunity to drive innovation, secure funding, and enhance their market potential.
For official details, visit the PRIP Scheme Webpage or email support-prip@pharma-dept.gov.in.
